171 related articles for article (PubMed ID: 29341179)
1. Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.
Schmitt A; Nguyen L; Zorza G; Ferré P; Pétain A
Br J Clin Pharmacol; 2018 May; 84(5):900-910. PubMed ID: 29341179
[TBL] [Abstract][Full Text] [Related]
2. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Delord JP; Ravaud A; Bennouna J; Fumoleau P; Favrel S; Pinel MC; Ferré P; Saliba F
Invest New Drugs; 2013 Jun; 31(3):724-33. PubMed ID: 22996801
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
5. Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.
Delord JP; Bennouna J; Mourey L; Bougaret J; Brandely-Talbot M; Ferré P
Clin Pharmacokinet; 2012 Jun; 51(6):357-64. PubMed ID: 22471295
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
Lobert S; Puozzo C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
[TBL] [Abstract][Full Text] [Related]
7. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.
Isambert N; Delord JP; Tourani JM; Fumoleau P; Ravaud A; Pinel MC; Petain A; Nguyen T; Nguyen L
Br J Clin Pharmacol; 2014 Mar; 77(3):498-508. PubMed ID: 24283925
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.
Bennouna J; Fumoleau P; Armand JP; Raymond E; Campone M; Delgado FM; Puozzo C; Marty M
Ann Oncol; 2003 Apr; 14(4):630-7. PubMed ID: 12649112
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
Delord JP; Tourani JM; Lefresne F; Pétain A; Pouget JC; Ravaud A
Cancer Chemother Pharmacol; 2013 Mar; 71(3):647-56. PubMed ID: 23299791
[TBL] [Abstract][Full Text] [Related]
10. Vinflunine.
Frampton JE; Moen MD
Drugs; 2010 Jul; 70(10):1283-93. PubMed ID: 20568834
[TBL] [Abstract][Full Text] [Related]
11. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
12. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer.
Paridaens R; Rixe O; Pinel MC; Wildiers H; Zorza G; Ferré P; Roche H
Cancer Chemother Pharmacol; 2012 Oct; 70(4):503-11. PubMed ID: 22864874
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.
Calvo E; Vermorken JB; Hiret S; Rodon J; Cortes J; Senellart H; Van den Brande J; Dyck J; Pétain A; Ferre P; Bennouna J
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1467-75. PubMed ID: 22382883
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.
Saito T; Iida S; Abe M; Jones K; Kawanishi T; Twelves C
J Pharm Pharmacol; 2013 Aug; 65(8):1168-78. PubMed ID: 23837584
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.
Johnson P; Geldart T; Fumoleau P; Pinel MC; Nguyen L; Judson I
Invest New Drugs; 2006 May; 24(3):223-31. PubMed ID: 16211365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
